Short Interest in Knight Therapeutics Inc. (OTCMKTS:KHTRF) Grows By 14.4%

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 472,500 shares, an increase of 14.4% from the January 15th total of 413,200 shares. Based on an average trading volume of 1,400 shares, the short-interest ratio is presently 337.5 days.

Knight Therapeutics Price Performance

Shares of OTCMKTS:KHTRF opened at $3.98 on Monday. Knight Therapeutics has a 12-month low of $3.48 and a 12-month high of $4.55. The business has a 50 day moving average of $3.78 and a two-hundred day moving average of $3.98.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.